Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 Injection for the Indication of Chronic Hepatitis B

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

On 6ix: 6ix.com/news/chongqing-genrix-biopharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-obtaining-the-notice-of-approval-for-clinical-trial-of-gr2302-injection-for-the-indication-of-chronic-hepatitis-b

Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 Injection for the Indication of Chronic Hepatitis B

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

All Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases